KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.

Abstract excerpt

KRAS G12C mutations define a small but clinically important molecular subset of metastatic colorectal cancer (mCRC), accounting for approximately 3% to 4% of cases and remaining associated with substantial unmet need after standard chemotherapy. Although direct KRAS G12C inhibitors have transformed treatment in other tumor types, their activity as monotherapy in mCRC has been modest, largely because colorectal...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Combined Chemotherapy Protocols
• Share to Cetuximab